Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 12/20 | 0.67 |
| ▸ | CASP7 | P55210 | 8/20 | 0.62 |
| ▸ | CASP1 | P29466 | 2/20 | 0.61 |
| ▸ | CASP9 | P55211 | 2/20 | 0.61 |
| ▸ | ECE1 | P42892 | 2/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19015889 | 1.00 | CASP3 (0.67) | CASP3CASP7CASP1CASP9ECE1 | |
| SCHEMBL7888300 | 1.00 | CASP3 (0.67) | CASP3CASP7CASP1CASP9ECE1 | |
| SCHEMBL7968958 | 0.90 | CASP3 (0.64) | CASP3CASP7CASP1CASP9REN | |
| SCHEMBL18471610 | 0.90 | CASP3 (0.64) | CASP3CASP7CASP1CASP9REN | |
| SCHEMBL7975507 | 0.90 | CASP3 (0.64) | CASP3CASP7CASP1CASP9REN | |
| SCHEMBL9961861 | 0.90 | CASP3 (0.64) | CASP3CASP7CASP1CASP9REN | |
| SCHEMBL19015824 | 0.88 | CASP3 (0.59) | CASP3CASP7CASP1CASP9CTSB | |
| SCHEMBL19015899 | 0.87 | CASP3 (0.82) | CASP3CASP7CASP1CASP9 | |
| SCHEMBL7970356 | 0.87 | CASP3 (0.82) | CASP3CASP7CASP1CASP9 | |
| SCHEMBL18782275 | 0.87 | CASP3 (0.65) | CASP3CASP7CASP1CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045524-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2015-06-02 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, VIP, CASP5 | CASP3 6/4885CASP7 13/4885CASP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.